Your browser doesn't support javascript.
loading
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Patil, Paurnima; Cieslak, Agata; Bernhart, Stephan H; Toprak, Umut H; Wagener, Rabea; López, Cristina; Wiehle, Laura; Bens, Susanne; Altmüller, Janine; Franitza, Marek; Scholz, Ingrid; Jayne, Sandrine; Ahearne, Matthew J; Scheffold, Annika; Jebaraj, Billy M C; Schneider, Christof; Costa, Dolors; Braun, Till; Schrader, Alexandra; Campo, Elias; Dyer, Martin J S; Nürnberg, Peter; Dürig, Jan; Johansson, Patricia; Böttcher, Sebastian; Schlesner, Matthias; Herling, Marco; Stilgenbauer, Stephan; Macintyre, Elizabeth; Siebert, Reiner.
Afiliación
  • Patil P; Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany.
  • Cieslak A; Diagnostic Haematology, Necker-Enfants Malades Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM), Paris, France.
  • Bernhart SH; Interdisciplinary Center for Bioinformatics, Transcriptome Bioinformatics, University of Leipzig, Leipzig, Germany.
  • Toprak UH; Bioinformatics and Omics Data Analytics, German Cancer Research Center, Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Wagener R; Division Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • López C; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
  • Wiehle L; Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany.
  • Bens S; Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Altmüller J; Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany.
  • Franitza M; Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Scholz I; Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany.
  • Jayne S; Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany.
  • Ahearne MJ; Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.
  • Scheffold A; Cologne Center for Genomics, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
  • Jebaraj BMC; Cologne Center for Genomics, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
  • Schneider C; Omics IT and Data Management Core Facility, German Cancer Research Center, Heidelberg, Germany.
  • Costa D; Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies, University of Leicester, Leicester, UK.
  • Braun T; Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies, University of Leicester, Leicester, UK.
  • Schrader A; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Campo E; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Dyer MJS; Department of Internal Medicine III, University of Ulm, Ulm, Germany.
  • Nürnberg P; Haematopathology Section, Hospital Clínic, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Dürig J; Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Johansson P; Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Böttcher S; Haematopathology Section, Hospital Clínic, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Schlesner M; Ernest and Helen Scott Haematological Research Institute, Department of Cancer Studies, University of Leicester, Leicester, UK.
  • Herling M; Cologne Center for Genomics, Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
  • Stilgenbauer S; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Macintyre E; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Siebert R; Department III of Internal Medicine, University Hospital Rostock, Rostock, Germany.
Genes Chromosomes Cancer ; 59(4): 261-267, 2020 04.
Article en En | MEDLINE | ID: mdl-31677197
ABSTRACT
T-cell prolymphocytic leukemia (T-PLL) is an aggressive tumor with leukemic presentation of mature T-lymphocytes. Here, we aimed at characterizing the initial events in the molecular pathogenesis of T-PLL and particularly, at determining the point in T-cell differentiation when the hallmark oncogenic events, that is, inv(14)(q11q32)/t(14;14)(q11;q32) and t(X;14)(q28;q11) occur. To this end, we mined whole genome and transcriptome sequencing data of 17 and 11 T-PLL cases, respectively. Mapping of the 14q32.1 locus breakpoints identified only TCL1A, which was moreover significantly overexpressed in T-PLL as compared to benign CD4+ and CD8+ T-cells, as the only common oncogenic target of aberrations. In cases with t(14;14), the breakpoints mapped telomeric and in cases with inv(14) centromeric or in the 3'-untranslated region of TCL1A. Regarding the T-cell receptor alpha (TRA) locus-TCL1A breakpoint junctions, all 17 breakpoints involved recombination signal sequences and 15 junctions contained nontemplated (N-) nucleotides. All T-PLL cases studied carried in-frame TRA rearrangements on the intact allele, which skewed significantly toward usage of distal/central TRAV/TRAJ gene segments as compared to the illegitimate TRA rearrangements. Our findings suggest that the oncogenic TRA-TCL1A/MTCP1 rearrangements in T-PLL occur during opening of the TRA locus, that is, during the progression from CD4+ immature single positive to early double positive thymocyte stage, just before physiologic TCL1A expression is silenced. The cell carrying such an oncogenic event continues maturation and rearranges the second TRA allele to achieve a functional T-cell receptor. Thereafter, it switches off RAG and DNTT expression in line with the mature T-cell phenotype at presentation of T-PLL.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Reordenamiento Génico / Leucemia Prolinfocítica de Células T / Predisposición Genética a la Enfermedad / Transcriptoma / Secuenciación Completa del Genoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Genes Chromosomes Cancer Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Reordenamiento Génico / Leucemia Prolinfocítica de Células T / Predisposición Genética a la Enfermedad / Transcriptoma / Secuenciación Completa del Genoma Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Genes Chromosomes Cancer Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Alemania